128 related articles for article (PubMed ID: 34959190)
1. Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR.
Yang L; Higashisaka K; Shimoda M; Haga Y; Sekine N; Tsujino H; Nagano K; Shimazu K; Tsutsumi Y
Biochem Biophys Res Commun; 2022 Jan; 588():175-181. PubMed ID: 34959190
[TBL] [Abstract][Full Text] [Related]
2. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.
Fu R; Tong JS
J Cell Mol Med; 2020 Jul; 24(13):7600-7608. PubMed ID: 32410348
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
Huynh FC; Nguyen D; Jones FE
Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
[TBL] [Abstract][Full Text] [Related]
5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
6. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
8. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.
Aghazadeh S; Yazdanparast R
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
11. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2
Kumar S; Das S; Sun J; Huang Y; Singh SK; Srivastava P; Sondarva G; Nair RS; Viswakarma N; Ganesh BB; Duan L; Maki CG; Hoskins K; Danciu O; Rana B; Li S; Rana A
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2205454119. PubMed ID: 36095190
[TBL] [Abstract][Full Text] [Related]
12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
13. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW; Forbes JT; Shah C; Wyatt SK; Manning HC; Olivares MG; Sanchez V; Dugger TC; de Matos Granja N; Narasanna A; Cook RS; Kennedy JP; Lindsley CW; Arteaga CL
Clin Cancer Res; 2009 Dec; 15(23):7266-76. PubMed ID: 19934303
[TBL] [Abstract][Full Text] [Related]
17. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
18. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
19. Heat shock factor 4 regulates lysosome activity by modulating the αB-crystallin-ATP6V1A-mTOR complex in ocular lens.
Cui X; Feng R; Wang J; Du C; Pi X; Chen D; Li J; Li H; Zhang J; Zhang J; Mu H; Zhang F; Liu M; Hu Y
Biochim Biophys Acta Gen Subj; 2020 Mar; 1864(3):129496. PubMed ID: 31786107
[TBL] [Abstract][Full Text] [Related]
20. Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements.
Sajadimajd S; Yazdanparast R
Mol Cell Biochem; 2015 Oct; 408(1-2):89-102. PubMed ID: 26116017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]